The efficacy of hepatitis C virus (HCV) treatment has increased over the last 5 years to nearly 100% for many patient groups. Patients with genotype (GT) 3 HCV infection, however, and specifically cirrhotic or treatment-experienced patients, have lower sustained virologic response (SVR) rates than patients with other GTs. Because GT 3 presents more clinical challenges than other GTs, this review focuses on the evolution and efficacy of direct-acting antiviral (DAA) treatment options for HCV GT 3 infection after the historical standard of care with pegylated interferon and ribavirin. Our objective was to review the SVR rates with available and late-pipeline DAAs for HCV GT 3 infection and discuss challenges with successful GT 3 treatment. Authors performed a literature search of the PubMed/MEDLINE database (inception to March 27, 2017) and narrowed the field to clinical trials published in English. Trials that evaluated alternative treatments, non-DAA historical treatment, and DAAs not currently indicated for HCV were excluded. Trials only involving patients with human immunodeficiency virus/HCV coinfection were also excluded. Additional trials were identified from a review of the ClinicalTrials.gov database. Authors further identified references from a review of literature citations and reviewed annual meeting abstracts from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver for pipeline and real-world GT 3 data. Phase III trial data were not available to support all GT 3 treatment recommendations found in the guidelines. The SVR rates were lower in treatment-experienced and cirrhotic patients with GT 3 than other HCV populations. Treatment failure was associated with resistance to current treatment regimens. Clinical studies included patients with various levels of advanced liver disease, but few patients with decompensated cirrhosis were represented. Recent advances in pharmacologic treatment with DAAs have greatly increased SVR rates in patients with all HCV GTs, but SVR rates for treatment-experienced cirrhotic patients with GT 3 are lower than for other GTs. Given the limited data and observed SVR rates in this patient population, the optimal therapy for patients with decompensated cirrhotic GT 3 HCV infection is not yet established. Newer agents and recommendations regarding baseline resistance are likely to evolve treatment strategies in the near future.
Between 2.5 and 4.7 million people in the United States currently have chronic hepatitis C virus (HCV) infection. 1 Chronic HCV infection is the primary cause of end-stage liver disease and the main reason for liver transplantation, liver-related death, and hepatocellular carcinoma (HCC) in the United States. 2 Worldwide genotype (GT) prevalence differs by geographic location; of the six major HCV GTs, GT 1 is the most common, both worldwide and nationally, and accounts for~75% of HCV infections in the United States. 3 Genotypes 2 and 3 constitutẽ 20-25% of the HCV infections in the United States, and GT 1-3 are the most common GTs in Europe. 4, 5 In the era of HCV treatment with pegylated interferon and ribavirin, GT 1 sustained virologic response (SVR) rates were in the 30-40% ranges, whereas GT 2 and 3 were considered "easy to treat," with combined SVR rates in the 80% range. 6 Since 2011, the U.S. Food and Drug Administration (FDA) has approved several highly effective direct-acting antivirals (DAAs) for the treatment of GT 1, with SVR rates now surpassing 90%. 7 Unfortunately, SVR rates did not demonstrate equal improvements for GT 3, establishing it as the difficult-to-cure strain of HCV.
Treatment recommendations are available for the six major HCV GT infections. 8 Although six regimens are available for GT 1, only two regimens are recommended for the treatment of GT 3. The SVR rates range from the high 50% to high 90% range for GT 3, depending on the regimen, treatment history, and stage of disease. 7, [9] [10] [11] [12] The SVR rates for first-wave DAAs for GT 3 were lower than those of other GTs, and treatment-experienced patients with cirrhosis had the lowest SVR rates among patients with HCV. 7, [9] [10] [11] [12] Currently available DAAs offer consistently high SVR rates for non-GT 3 treatment-experienced and cirrhotic patients. 7 Recently approved and pipeline agents have demonstrated high SVR rates for GT 3 in clinical trials including treatment-experienced and cirrhotic patients. [12] [13] [14] [15] [16] [17] The prognosis for cure of patients with GT 3 increased in mid-2016 after the approval of new DAAs, yet the gap in SVR rates has not closed for all currently available regimens among all patient populations.
Because GT 3 presents more clinical challenges than other GTs, this review focuses on the evolution and efficacy of DAA treatment options for HCV GT 3 infection after the historical standard of care with pegylated interferon and ribavirin. The objective was to review the SVR rates with available treatment options and late-pipeline agents for HCV GT 3 and discuss challenges with successful GT 3 treatment.
Methods
A search of PubMed/Medline (inception to March 27, 2017 ) was performed using the terms hepatitis C and genotype 3 to identify relevant articles. All English-language titles were evaluated. Authors excluded trials that evaluated alternative treatments (e.g., non-DAAs); non-DAA historical treatment exclusively of interferon or pegylated interferon with or without ribavirin; and DAAs not indicated or FDA approved for GT 3 (e.g., first-generation protease inhibitors) or not in the pipeline for GT 3 HCV treatment. Trials only involving human immunodeficiency virus/HCV coinfection were also excluded. Additional ongoing relevant trials were identified from a review of the ClinicalTrials.gov database using the search terms hepatitis C and genotype 3. Other references were included based on a review of the literature of select articles. Annual meeting abstracts from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver were reviewed for pipeline and real-world data for GT 3.
Genotype 3 DAA Treatment
Infection with HCV GT 3 poses a challenge to successful treatment that is not fully elucidated. Various theories exist regarding how the pathogenesis of GT 3 infection may contribute to the decreased SVR rates seen in patients infected with GT 3 compared with other GTs. One documented difference is the higher incidence of steatosis with GT 3 compared with other HCV GTs. The presence of steatosis was found to impact SVR rates negatively after treatment with the historical standard of care. 18 An international randomized controlled trial assessed the impact of various clinical factors including hepatic steatosis and HCV RNA level, on-treatment response, and relapse in treatment-naive patients with GT 2 or GT 3 after treatment with pegylated interferon and ribavirin for 24 weeks. 18 Among the 505 GT 3 patients, 79.2% achieved SVR and 15.6% relapsed; patients with steatosis had higher rates of relapse after HCV treatment than patients without steatosis for both low (17.4% vs 2.5%) and high (20.9% vs 8.8%) baseline HCV RNA levels. The presence of steatosis was an independent predictor of relapse for GT 3. Reversal of steatosis was seen in GT 3 patients who achieved SVR.
Similarly, SVR was associated with a significant reduction in steatosis among GT 3 patients in a study of both GT 1 and GT 3 patients who had both pretreatment and posttreatment liver biopsy specimens. 19 In contrast, treatment outcome had no effect on steatosis among patients with GT 1, and no reversal of steatosis was observed in GT 3 patients who failed HCV therapy. A GT-specific host-signaling pathway is a proposed mechanism for the relationship between steatosis and GT 3 treatment failure, although other host-viral factors may also play a role.
Accelerated progression to cirrhosis and HCC was also demonstrated in patients with GT 3 infection. Among 1189 Swiss patients, GT 3 infection was independently identified as a risk factor for accelerated rates of fibrosis. 20 A meta-analysis and review of GT 3 and liver fibrosis progression confirmed this risk. 21 GT 3 was found to increase the risk of developing cirrhosis and HCC compared with GT 1 infection among U.S. veterans. 22 These findings were confirmed in a prospective study of American Indian/Alaska Natives that identified GT 3 infection as an independent risk factor for development of end-stage liver disease, HCC, liver-related death, and need for liver transplantation. 23 The independent effect of GT 3 in liver disease progression raises concerns regarding the urgency of treatment for patients with GT 3.
In the United States, HCV treatment guidelines are published by the AASLD in collaboration with the Infectious Diseases Society of America (IDSA). 24 These guidelines are shown in Table 1  (as of March 27, 2017) . The AASLD Web site (http://www.hcvguidelines.org) provides the current HCV guidance; the online document is updated in real time as new data become available. 24 Figure 1 shows the SVR rates reported in select clinical trials that support the recent and current DAA guidance from 2014 until March 2017. [9] [10] [11] [12] Since July 6, 2016, the guidelines have recommended the use of daclatasvir and sofosbuvir or sofosbuvir/velpatasvir for 12 weeks as the two options for treatment-naive noncirrhotic patients with GT 3. 24 Pretreatment resistance testing is recommended for treatment-naive patients with compensated cirrhosis; the presence of specific resistance mutations necessitates the addition of ribavirin, and if daclatasvir and sofosbuvir are used, the extension of treatment duration to 24 weeks is also recommended. Similarly, all treatment-experienced GT 3 patients without cirrhosis require resistance testing to assess the need for concomitant ribavirin use ( Figure 2 ). Ribavirin is dosed based on weight, unless otherwise specified (1000 mg/day if weight less than 75 kg; 1200 mg/day if weight is 75 kg or more).
The presence of cirrhosis is known to impact SVR negatively, although the magnitude of the change varies by GT and degree of cirrhosis. Trials often restrict enrollment to patients with compensated (Child-Turcotte-Pugh [CTP] class A) cirrhosis and exclude the more difficultto-cure decompensated (CTP classes B and C) cirrhotic patients. Other decompensated trials combine CTP classes B and C for analysis and contain small numbers of patients with CTP class C. These exclusions limit the availability of important data in patients with poorer baseline prognoses. Evaluation of available studies elucidates the paucity of information on patients with CTP class C and their poor SVR rates in both clinical and real-world trials ( Figure 3) . 25, 26 The DAAs target specific regions on the HCV virus: drugs with the suffix "-previr" are protease inhibitors targeting the NS3/4A region; drugs with the suffix "-asvir" are replication complex inhibitors targeting the NS5A region; and drugs with the suffix "-buvir" are polymerase inhibitors targeting the NS5B region. Sofosbuvir, as an NS5B agent, is further identified as a nucleotide NS5B polymerase inhibitor, in contrast to dasabuvir, a nonnucleoside NS5B polymerase inhibitor. DAA use in GT 3 patients began with the FDA approval of sofosbuvirbased regimens in December 2013. 9 In January 2014, the inaugural online AASLD/IDSA guidance recommended the use of sofosbuvir and ribavirin for 24 weeks for GT 3 patients based on clinical trials. 7, 9 This regimen was recommended over regimens pegylated interferon-based due to its oral route of administration and preferable adverse drug reaction (ADR) profile.
The POSITRON trial revealed that the SVR rate for the mix of treatment-naive and treatment-experienced GT 3 cirrhotic patients was considerably lower compared with the GT 2 cirrhotic patients (21% vs 94%) after 12 weeks of treatment with sofosbuvir and ribavirin. 27 Further trials evaluated whether treatment duration longer than 12 weeks for GT 3 patients could improve SVR rates. In the FISSION trial, SVR rates for treatment-naive GT 3 patients were similar with sofosbuvir and ribavirin for 12 weeks and historical standard of care with pegylated interferon and ribavirin for 24 weeks (56% vs 63%). 28 This trial likely had a higher SVR rate compared with the SVR rate in the POSITRON trial because all patients were treatment naive. The FUSION trial showed an improved SVR with sofosbuvir and ribavirin by extending therapy to 16 weeks of treatment, but the 62% SVR rate still lagged behind the accepted SVR rates for patients with GT 1 or GT 2. 27 Subsequent clinical trials again increased the length of therapy as an attempt to improve GT 3 SVR rates. The phase III VALENCE trial included both treatment-naive and treatmentexperienced patients. 9 By extending sofosbuvir and ribavirin treatment to 24 weeks, it resulted in an SVR rate of 85% in the 250 patients (24% of whom were cirrhotic). Treatment-experienced patients with cirrhosis had an underwhelming SVR rate of 62%. Nonetheless, these data supported the FDA-approved 24-week length of treatment of sofosbuvir and ribavirin for GT 3 patients because this was the only oral regimen available for GT 3 at the time. Although the 24-week treatment SVR rate was higher than the 12-week treatment SVR rates, it still was lower than SVR rates observed in GT 1 and GT 2 cohorts. Hence GT 3 emerged as the challenging GT with decreased DAA treatment success compared with other GTs.
Attempts to improve SVR also included the addition of pegylated interferon to DAA and ribavirin treatment. The LONESTAR-2 phase II trial evaluated the efficacy of sofosbuvir, pegylated interferon, and ribavirin for 12 weeks in cirrhotic and noncirrhotic treatment-experienced GT 2 and GT 3 patients. 29 The SVR rate for the 24 GT 3 patients was 83% overall including both the cirrhotic and noncirrhotic patients. The reversion to treatment with pegylated interferon for GT 3 patients was not ideal due to ADRs, but the improved efficacy spurred additional investigation.
Similar to the VALENCE results, the BOSON study found an 84% SVR rate after treatment with sofosbuvir and ribavirin for 24 weeks in 182 GT 3 patients, and a 77% SVR rate in the 34 treatment-experienced patients with cirrhosis. 30 After adding pegylated interferon to sofosbuvir and ribavirin for 12 weeks, the SVR rates were 93% in 181 treated patients and 86% in the 35 treatment-experienced patients with cirrhosis. This substantial increase in SVR rate compared with all oral treatment for this population of GT 3 patients was the basis for the guidance's previous inclusion of the use of sofosbuvir, pegylated interferon, and ribavirin for 12 weeks in GT 3 treatment.
Patients with GT 3 who failed a 12-week course of sofosbuvir and ribavirin during previous clinical trials (POSITRON, FISSION, and FUSION) also saw benefit with retreatment using sofosbuvir, pegylated interferon, and ribavirin.
Results of an open-label treatment showed higher SVR rates in patients treated with sofosbuvir, pegylated interferon, and ribavirin for 12 weeks compared with sofosbuvir and ribavirin for 24 weeks (91% vs 63%), corroborating that the addition of pegylated interferon substantially improved SVR while allowing for a shorter course of therapy. 31 Enthusiasm for continued use of interferon in the era of DAAs was understandably muted given its well-known toxicities including multiple laboratory abnormalities and ADRs. In comparison, common ADRs in patients treated with sofosbuvir and ribavirin included fatigue, headache, and anemia. Discontinuation rates due to ADRs were low in sofosbuvir and ribavirin treatment regimens; placebo arms had higher discontinuation rates (4%) than treatment arms (2%) in the GT 2 and GT 3 groups. 27 Current Treatment: Dual DAAs Online guidance on HCV was updated in July 2016 after the approval of sofosbuvir/velpatasvir to remove the recommendations for use of sofosbuvir, pegylated interferon, and ribavirin, or sofosbuvir and ribavirin for HCV GT 3. 24 Current GT 3 treatment involves use of oral therapy with two DAAs. 24 Because these agents directly target viral replication, resistance is a concern. The later section "Role of Resistance in GT 3" discusses the impact of baseline resistance on treatment success and the impact of previous treatment failure due to resistance on future treatment success with these regimens.
Daclatasvir and Sofosbuvir
Daclatasvir is an NS5A inhibitor with activity against GT 1-6. It is a recommended therapy in combination with sofosbuvir with or without ribavirin for HCV GT 3 in the United States. 24 It is available as 30-, 60-, and 90-mg tablets to allow for dosage adjustments based on potential drug-drug interactions.
The randomized phase III ALLY-3 trial included a total of 152 patients (101 treatment naive and 51 treatment experienced) who received a 12-week course of therapy of daclatasvir and sofosbuvir. 10 Patients previously treated with NS5A inhibitors were excluded. The overall SVR rate was 89%; among the 32 patients enrolled with confirmed CTP class A cirrhosis, the SVR rate was markedly reduced at 63% (20/32), compared with 96% (105/109) in patients without cirrhosis. The results demonstrated that a 12-week course of therapy with daclatasvir and sofosbuvir was highly effective for noncirrhotic patients, but the presence of cirrhosis undermined its success. No adverse events led to discontinuation of treatment with daclatasvir and sofosbuvir, and the most common ADRs were fatigue, nausea, and headache.
The ALLY-3+ trial evaluated whether or not the addition of weight-based ribavirin to daclatasvir and sofosbuvir could improve SVR in patients with GT 3 and advanced liver disease.
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A total of 50 patients were included: 24 received 12 weeks of therapy, and 26 received 16 weeks of treatment. Most patients were treatment experienced, with 62% having received interferon-based therapy and 12% having received sofosbuvir-based therapy; the remaining 26% were treatment naive. Most patients had compensated cirrhosis as consistent with METAVIR stage 4 (36/50), whereas the remainder had advanced fibrosis with METAVIR stage 3 (14/ 50). The intent-to-treat SVR rates were 90% (45/ 50) overall, 88% (21/24) for the 12-week arm, and 92% (24/26) for the 16-week arm, indicating that the addition of ribavirin to daclatasvir and sofosbuvir improves SVR rates in patients with compensated cirrhosis. No virologic breakthroughs occurred on treatment, but two patients relapsed in both groups. Subanalysis of SVR by stage demonstrated that the highest SVRs were achieved in the advanced fibrosis group (SVR 100%) with a decline in SVR as patients progress to cirrhosis, with overall SVR rates of 86% (31/36) in all patients with cirrhosis and 87% (26/30) in treatment-experienced patients with cirrhosis. Although the subanalysis was limited by the small number of patients, the data underscore the challenges of successful treatment of patients with cirrhosis and those who are treatment experienced.
Additional data in patients with GT 3 and advanced liver disease were reported as part of larger studies with mostly GT 1 patients. In the 12-week ALLY-1 trial of daclatasvir, sofosbuvir, and ribavirin 600 mg/day, six GT 3 patients were included in the decompensated cirrhosis arm, three each classified as CTP classes B and C. 32 Five of the six patients with advanced cirrhosis achieved SVR. The one patient who relapsed after treatment had CTP class C cirrhosis. Among the 11 patients with GT 3 in the posttransplantation arm, 91% (10/11) achieved SVR. A major limitation of this trial was the small number of patients with GT 3.
The French compassionate use program reported initial data on the use of 12 or 24 weeks of daclatasvir and sofosbuvir with or without ribavirin in cirrhotic GT 3 patients. 33 The SVR rate was high at 92% in noncirrhotic patients treated with a 12-week course of therapy, and no improvement in SVR occurred with a treatment extension to 24 weeks. Cirrhotic patients did benefit from extension of therapy with SVR rates of 76% in the 12-week arm and 88% in the 24-week arm. Treatment arms varied in size and were small in the decompensated groups, thus limiting interpretation regarding the effect of treatment duration or concomitant use of ribavirin.
The European compassionate use program included 102 GT 3 patients and used 24 weeks of treatment in both treatment-naive and treatment-experienced patients without other treatment options. 25 The SVR rates were 80% (12/ 15) with daclatasvir and sofosbuvir, and 87% (13/15) with daclatasvir, sofosbuvir, and ribavirin in CTP class B patients. For CTP class C patients, the SVR rates were 78% (7/9) after treatment with daclatasvir and sofosbuvir, and 100% (2/2) SVR after treatment with daclatasvir, sofosbuvir, and ribavirin. 25 The addition of ribavirin and extension of therapy seemed to favor improved outcomes. However, these groups of patients are small, and treatment with this regimen had the highest retail cost of available regimens at the time of publication. Current guidelines recommend 24 weeks of daclatasvir and sofosbuvir with weight-based ribavirin in treatment-experienced compensated cirrhotic patients because this patient population has lower SVR rates than treatment-naive patients. In contrast, the recommended treatment for decompensated cirrhotic patients is 12 weeks of daclatasvir, sofosbuvir, and ribavirin 600 mg/ day, despite the lack of phase III trial data (Table 1) . Providers may consider the use of 24 weeks of sofosbuvir and daclatasvir in ribavirin-ineligible decompensated GT 3 patients, although this option can be cost prohibitive.
Sofosbuvir/Velpatasvir
Velpatasvir, a second-generation NS5A inhibitor, was FDA approved on June 28, 2016, in a fixed-dose combination with sofosbuvir in patients with GT 1-6. Its approval marked a change in the treatment approach for GT 3 because the use of the dual DAA-based therapy is superior to and thus replaced the previous therapeutic option of sofosbuvir with ribavirin. Investigators compared sofosbuvir/velpatasvir for 12 weeks (277 patients) with sofosbuvir and ribavirin for 24 weeks (275 patients) in GT 3 patients in the ASTRAL-3 study. 12 Patients were mostly treatment naive (74%), although the study included 71 patients who were previously treated with an interferon-based regimen with or without ribavirin, and 163 patients who had compensated cirrhosis. The SVR rates were 95% (95% confidence interval [CI] 92-98%) for the sofosbuvir/velpatasvir arm and 80% (95% CI 75-85%) for the sofosbuvir and ribavirin arm (p<0.001). Rates were lower for both treatmentnaive and treatment-experienced cirrhotic patients, as well as treatment-experienced noncirrhotic patients. Previously treated noncirrhotic and cirrhotic patients had SVR rates of 91% and 89% in the sofosbuvir/velpatasvir group but only 71% and 58% in the sofosbuvir and ribavirin group, respectively (Figure 1) . No ontreatment failures occurred in the sofosbuvir/ velpatasvir arm, and only one on-treatment failure occurred in the sofosbuvir and ribavirin arm. Laboratory abnormalities were uncommon and more likely to occur in patients treated with ribavirin. The most commonly reported ADRs included fatigue, headache, and nausea, and they were reported more often in patients treated with ribavirin. All nine treatment discontinuations were due to ADRs in the ribavirin arm.
The ASTRAL-4 study evaluated the use of sofosbuvir/velpatasvir in GT 1-6 patients with decompensated cirrhosis. 26 Of the 267 patients in the trial, only 39 had GT 3. The small number of patients in the GT 3 group makes it difficult to draw conclusions about efficacy in this particular population. The SVR rate was 50% for patients treated with sofosbuvir/velpatasvir for both 12 and 24 weeks, suggesting that extending the length of therapy with this regimen may not offer improved SVR rates, although this tactic had been used with other available DAA regimens. The highest SVR rate of 85% was reported in the arm treated with sofosbuvir/velpatasvir plus ribavirin for 12 weeks, indicating that ribavirin still plays an important role in the treatment of decompensated cirrhotic patients even with newer DAAs.
Sixty-nine GT 1-3 patients (26% cirrhotic) who failed 4-12 weeks of a sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir regimen during phase II trials were retreated with sofosbuvir/velpatasvir and ribavirin for 24 weeks. A total of 81% of the 16 GT 3 patients achieved SVR. 34 Resistance played a role in the treatment failures. Small groups of patients were included in this trial, and the issue of retreatment for DAA failures warrants further exploration. Select Late-Phase Investigational Agents for GT 3: Dual and Triple DAAs Treatment for HCV is evolving rapidly, and pipeline agents hold promise for even greater success in achieving SVR. Fixed-dose oral pangenotypic treatment options are currently in phase III trials, and several clinical trials are evaluating shortened duration HCV treatment. Investigational combinations that include a protease inhibitor will likely be limited to use in patients without cirrhosis or those with CTP class A cirrhosis due to concerns for hepatic decompensation with protease inhibitors.
Sofosbuvir/Velpatasvir/Voxilaprevir
The fixed-dose combination of voxilaprevir, an NS3/4A protease inhibitor, with sofosbuvir/ velpatasvir received FDA breakthrough therapy designation for GT 1 patients who have failed treatment with an NS5A inhibitor and is under investigation for use in GT 1-6. The phase III POLARIS-3 trial evaluated compensated cirrhotic DAA-naive (but 31% treatment experienced with interferon-based regimens) GT 3 patients, and it found SVR rates of 96% (106/110) in patients treated with 8 weeks of sofosbuvir/velpatasvir/ voxilaprevir and 96% (105/109) in patients treated with 12 weeks of sofosbuvir/velpatasvir. 13 This trial demonstrated similar efficacy with both regimens for pegylated interferonexperienced patients and treatment-naive patients. POLARIS-1 evaluated DAA-experienced patients with GT 1-6 (46% cirrhotic in the treatment group) and found an SVR rate of 95% (74/ 78) in GT 3 patients treated with sofosbuvir/ velpatasvir/voxilaprevir for 12 weeks.
14 In POLARIS-4, which evaluated DAA-experienced GT 1-4 patients (46% cirrhotic), GT 3 SVR rates were 94% (51/54) after 12 weeks of treatment with sofosbuvir/velpatasvir/voxilaprevir and 85% (44/ 52) after 12 weeks of sofosbuvir/velpatasvir. 15 These results demonstrated an improved SVR rate with the addition of a third DAA agent in DAA-experienced patients.
Elbasvir/Grazoprevir + Sofosbuvir
The C-SWIFT trial evaluated the fixed-dose combination of elbasvir (NS5A inhibitor) and grazoprevir (NS3/4A protease inhibitor) plus sofosbuvir in patients with GT 3; SVR rates were 93% for the 15 noncirrhotic patients who were treated for 8 weeks, 100% for the 14 noncirrhotic patients who were treated for 12 weeks, and 91% in 11 compensated cirrhotic patients who were treated for 12 weeks. 35 This proofof-concept study supported the development of a triple DAA combination for a potentially sub-12-week length of therapy for noncirrhotic patients. The C-ISLE trial evaluated the combination of elbasvir/grazoprevir plus sofosbuvir, with or without ribavirin for 8 or 12 weeks, and without ribavirin for 16 weeks in 100 treatmentnaive and treatment-experienced CTP class A patients. 36 The SVR rates were 91% (21/23) in the 8-week arm of elbasvir/grazoprevir plus sofosbuvir and ribavirin and 100% (73/73) across the other four treatment arms. Elbasvir/ grazoprevir is approved for GT 1 and 4 in the United States; use is limited to noncirrhotic or compensated cirrhotic patients. Concerns for hepatic decompensation limit the use of protease inhibitors in patients with cirrhosis, with contraindications for use in patients with CTP class B or C. 37 Of note, the combination of elbasvir/ grazoprevir and sofosbuvir for 12 weeks is approved for GT 3 treatment-naive patients in Canada.
Ruzasvir/Grazoprevir/MK-3682
The manufacturer evaluated the use of a novel nucleotide analog NS5B polymerase inhibitor, MK-3682, with 300-mg or 450-mg doses in the fixed-dose combinations of elbasvir/grazoprevir/ MK-3682 and ruzasvir/grazoprevir/MK-3682 in treatment-naive noncirrhotic and compensated cirrhotic GT 3 patients in the phase II trial C-CREST-2. 38 The second-generation NS5A inhibitor, ruzasvir (MK-8408), is pan-genotypic; it has more potency against GT 2 and GT 3 than elbasvir. Part A of C-CREST-2 demonstrated a 5% SVR rate increase in each arm with use of ruzasvir over elbasvir (95% vs 90% in the MK-3682 300-mg arms; 91% vs 86% in the MK-3682 450-mg arms). 39 Therefore, the combination of ruzasvir/grazoprevir/MK-3682 moved forward in part B of the C-CREST-2 trial and other clinical trials. Part B of the C-CREST-1 and -2 trials included 315 GT 3 treatment-naive or treatmentexperienced (with pegylated interferon and ribavirin) patients with or without compensated cirrhosis. 16 All patients were treated once/ day with ruzasvir/grazoprevir/MK-3682 (450 mg), with or without ribavirin for 8, 12, or 16 weeks. The SVR rates were similar in cirrhotic and noncirrhotic patients in the 12-week arm with ribavirin (96% vs 98%), 12-week arm without ribavirin (100% vs 98%), and in the 16-week arm with ribavirin (96% vs 98%). Use of this combination is under evaluation in GT 3 patients who have failed previous sofosbuvir-based DAA treatment regimens; this population is in need of additional treatment options. 40 
Glecaprevir/Pibrentasvir
The combination of glecaprevir/pibrentasvir (NS3/4A protease inhibitor and NS5A inhibitor) received FDA breakthrough therapy designation for GT 1 on September 30, 2016. A benefit of pibrentasvir is that it demonstrated a higher genetic barrier to NS5A resistance-associated substitutions (RASs) compared with other available NS5A inhibitors. The combination was studied with or without ribavirin in GT 3 patients in early-phase trials. The phase III ENDURANCE-3 trial compared glecaprevir/pibrentasvir with daclatasvir and sofosbuvir in treatment-naive noncirrhotic GT 3 patients. 41 Preliminary data presented at the 2016 AASLD meeting demonstrated an SVR rate of 95% (149/ 157) after 8 weeks of treatment; completion of the study was scheduled for December 2016; full results will likely be presented at a conference in 2017. The SURVEYOR-II trial included 131 GT 3 patients treated with glecaprevir/pibrentasvir; SVR rates for treatment-experienced noncirrhotic patients were 91% (20/22) in the 12-week arm and 96% (21/22) in the 16-week arm. 17 The SVR rates in compensated cirrhotic patients were 98% (39/40) in the treatmentnaive 12-week arm, and 96% (45/47) in the treatment-experienced 16-week arm. Use of this combination is also under evaluation in other GT 3 populations with limited treatment options including renally impaired patients in the EXPE-DITION-4 trial. 42 The SVR rate was 98% (102/ 104; one patient discontinued treatment and one was lost to follow-up), but the study included only 11 GT 3 patients. This regimen may be an additional option for GT 3 compensated cirrhotic patients.
Investigational HCV agents appear promising for increasing the armamentarium for the treatment of GT 3. Given the challenges of successful therapy, some emerging combinations include triple DAA therapy with NS3/4A, NS5A, and NS5B agents. Although investigational agents have demonstrated success in noncirrhotic and compensated cirrhotic patients, the lack of demonstrated safety in patients with decompensated liver disease is concerning. Historically, use of NS3/4A protease inhibitors was limited to patients with compensated cirrhosis (i.e., simeprevir, paritaprevir, grazoprevir). Even among patients with CTP class A cirrhosis, there is concern for worsening liver disease with protease inhibitors, as demonstrated with the recommendations for hepatic monitoring for elevations in alanine aminotransferase level during therapy as a precaution for identifying decompensation. Despite the expected additional highly effective therapies for GT 3, the options for patients with CTP class B or C remain limited, underscoring the need to treat patients with HCV earlier in their disease process when SVR rates are well above 90%.
Role of Resistance in GT 3
In HCV, the virus undergoes prolific replication, and the HCV polymerase lacks proofreading capacity, thus making the virus highly error prone. 43 The virus can carry specific amino acid substitutions, or RASs, at baseline, or the virus can develop resistance through exposure to DAAs. In contrast to interferon's actions on the host immune system, the DAA therapies act directly on the HCV virus and thus are more susceptible to resistance. Resistance substitutions at the NS5A position can reduce efficacy of the NS5A DAAs. Sofosbuvir resistance, associated with NS5B mutations, is not likely to play a clinical role in GT 3 treatment failure. In the FIS-SION trial, none of the 74 patients who relapsed after treatment with sofosbuvir and ribavirin for 12 weeks had developed NS5B resistance, and no clinically relevant resistance-associated NS5B mutations were discovered in any of the other phase III sofosbuvir trials. 28 The impact of baseline RASs on SVR is not fully understood and is likely influenced by both host and viral factors. In many studies, the number of patients with baseline RASs is small, and patients may have the virus with multiple mutations, further complicating interpretation of the significance of specific mutations. Testing for baseline resistance is currently recommended for patients with GT 3 who have cirrhosis or who have previous treatment experience. 24 Although multiple mutations may exist, the presence of the Y93 mutation necessitates the addition of ribavirin to a treatment course. Baseline resistance testing is not indicated in patients with decompensated cirrhosis because the recommended therapy already includes ribavirin.
In the ALLY-3 study of daclatasvir and sofosbuvir, baseline RASs were assessed at NS5A positions M28, A30, L31, and Y93. 10 Few patients had baseline RASs, but the SVR rates among patients with baseline NS5A RASs were lower if patients were also cirrhotic. NS5B RASs were not detected. Both NS5A and NS5B RASs were assessed at baseline and at the time of virologic failure in the ALLY-3+ study that added ribavirin to the treatment course of daclatasvir and sofosbuvir. Treatment-emergent NS5A RASs, specifically Y93H, were present in the four patients who relapsed. One was a treatment-naive patient with advanced liver disease who was treated for 12 weeks and carried the Y93H mutation at baseline. No NS5A or NS5B RASs were detected at baseline in the remaining three treatment-experienced patients who failed; this may implicate other reasons for virologic failure.
Early sofosbuvir/velpatasvir trials offered limited data regarding the impact of resistance in GT 3 patients. In a phase II study of treatmentnaive noncirrhotic GT 3 patients, baseline NS5A sequencing was performed. 44 Among patients treated with the currently available strength of sofosbuvir 400 mg/velpatasvir 100 mg, the SVR rate was 100% (19/19) in patients without baseline NS5A resistance and only 86% (6/7) in patients with baseline NS5A mutations.
Subsequently, in the ASTRAL-3 study of sofosbuvir/velpatasvir, 84% (231/274) of patients did not have any baseline NS5A RASs and had an SVR rate of 97%. 12 In comparison, the SVR rate was 88% (38/43) in patients who had a baseline NS5A RAS (A30K, L31M, and Y93H). The lowest SVR rate was 84% (21/25) in patients with the baseline Y93H substitution. The group of 11 patients who relapsed included one patient who was reinfected and 10 patients who were found to have the Y93H mutation at follow-up. All 10 patients with NS5B RASs at baseline achieved SVR; this is consistent with prior reports that sofosbuvir resistance is not clinically significant.
Limited data are available from the ASTRAL-4 study of sofosbuvir/velpatasvir in patients with decompensated cirrhosis. 26 A total of 13 GT 3 patients had virologic failure; baseline NS5A RASs were reported in 3 patients at baseline, but all 13 had NS5A RASs at virologic failure, with the Y93H variant identified in all GT 3 failures. NS5B RASs were also identified, although at low levels that were not expected to contribute to failure.
Of the 16 patients who had reached the primary end point at the time of interim analysis in the sofosbuvir/velpatasvir retreatment trial, 100% (3/3) of the patients without baseline RASs achieved SVR, and 77% (10/13) of the patients with RASs achieved SVR. 34 Relative to GT 1 and GT 2, the GT 3 patients had a higher percentage of RASs and lower SVR rate when RASs were present. This study involved a small number of patients but suggested that GT 3 patients have more RASs and failure after treatment with RASs when compared with GT 1 or GT 2.
In the C-SWIFT study, two of the cirrhotic patients who were treated with elbasvir/grazoprevir and sofosbuvir relapsed; one had wildtype virus at baseline and relapsed, and the other developed the Y93H NS5A resistance at relapse and maintained Q168R NS3 resistance from baseline through relapse. 35 In the C-CREST study, 47% of the 43 GT 3 patients who were treated with ruzasvir/grazoprevir/MK-3682 had baseline NS5A RASs; 85% (17/20) achieved SVR. One of the three relapsers had Y93H resistance at the time of failure. In comparison, all 23 patients without baseline NS5A RASs achieved SVR. 39 In part C of the C-CREST-1 and -2 trials, 100% (8/8) of GT 3 patients who failed treatment with a triple regimen in an earlier phase of the study obtained SVR after treatment with 16 weeks of ruzasvir/grazoprevir/MK-3682 and ribavirin. 45 At the time of relapse following initial therapy, 88% (7/8) had NS5A RASs, 100% (8/8) had NS3 RASs, and 0% had NS5B RASs.
The reduced SVR rates in patients with baseline NS5A substitutions are a relatively novel concern for HCV therapy. Limited overall data suggest that the presence of substitutions decreases SVR, and some particular mutations (i.e., Y93H) may be more detrimental to SVR than others. The presence of RASs among clinical studies in some cases offers conflicting evidence for relevance of these mutations, suggesting that other factors may also impact SVR. The common theme is that the Y93H mutation has proven most threatening to SVR in GT 3 patients, although it would be premature to dismiss the impact of other mutations or the impact of combined mutations. Thus optimal management to overcome the effect of these substitutions is not clear. The addition of ribavirin and/or extension of therapy may ultimately be required to optimize treatment in some patients with HCV GT 3 infection. Because currently available DAA retreatment data include few cirrhotic GT 3 patients, resistance data are limited, and optimal retreatment strategies are unconfirmed.
Recommendations for baseline GT 3 NS5A resistance testing will likely follow with more available information on the impact of baseline RASs on SVR. Resistance testing can be cost prohibitive and is not universally available; thus it is not routinely recommended outside the United States. In addition to concerns for baseline RASs impacting SVR, another concern with NS5A resistance substitutions is the long-term persistence of resistance. Patients who failed DAA therapy with the NS5A agent ledipasvir were found to have NS5A RASs at least 2 years after completing HCV therapy. 46 The impact of selection and persistence of resistance on DAA therapy is not clear. Class resistance poses a new challenge to effective HCV therapy because our current DAA armamentarium consists of only three medication classes.
Conclusion
Recent advances in pharmacologic treatment with DAAs have greatly increased SVR rates in patients with all HCV GTs, but SVR rates with treatment-experienced cirrhotic patients with GT 3 are lower than the nearly 100% standard for patients with other GTs. Studies include patients with various levels of advanced liver disease, including decompensated cirrhosis, yet few patients with CTP class C are represented in these studies. Overall, there is a trend in declining SVR with increasing CTP, illustrating the difficulty in treating patients with advanced liver disease. The optimal therapy for patients with GT 3 and CTP class C cirrhosis is not clear, given the limited data and low observed SVR rates in this patient population.
Current HCV guidelines offer recommendations for increased length of therapy with daclatasvir and sofosbuvir beyond what was studied in clinical trials for patients with compensated cirrhosis, but shorter therapy for patients with decompensated cirrhosis despite lack of clinical trial data; additional data on this patient population are needed.
Treatment failure carries new risks of resistance that may have a class effect and compromise future DAA regimens. Extensions of therapy and/ or the addition of ribavirin are strategies that have been evaluated to maximize SVR. Future regimens must have a high barrier to resistance and high efficacy in treatment-experienced (and DAAexperienced) patients to be successful. It is likely that future therapies will offer the greatest improvements in SVR and potentially shorter treatment courses when three DAAs are combined for maximum antiviral effect. Pipeline agents that offer improved SVR rates compared with early 2016 GT 3 treatment will likely be commercially available later in 2017. However, it is likely that new therapies will be limited to patients with less advanced liver disease due to the potential dangers of using protease inhibitors in patients with decompensated cirrhosis. To fully utilize the potential of current and pipeline agents, it is important to treat and cure patients with HCV, especially GT 3, earlier in their disease.
